FE 203799
As of the edition of 20 October 2026, FE 203799 is a protein: went quiet in 2019; acts on GLP2R.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2019
- Kind
- Protein
- Registered trials
- 2, 1 stopped early
- Disease areas
- Digestive system; Blood and lymph; Cancer; Immune system; Mouth and teeth
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of FE 203799.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| GLP2R | Glucagon-like peptide 2 receptor | O95838 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 2 | 1 | 0 | 1 |
| All trials | 2 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| GlyPharma Therapeutics | Lead sponsor of trials | 2018 to now |